NASDAQ · CV
Healthcare · Medical - Equipment & Services
$6.83
Down-$0.13 (-1.90%)
Updated Nov 2, 2026, 8:10 PM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CV
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
CV closed at $6.83 after 20 trading sessions, up 3.72% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $6.99 | $7.10 | $6.79 | $6.83 | 86.78K |
| Oct 29, 2026 | $7.10 | $7.23 | $6.89 | $6.94 | 101.94K |
| Oct 28, 2026 | $6.78 | $7.13 | $6.77 | $7.06 | 220.28K |
| Oct 27, 2026 | $6.94 | $6.98 | $6.71 | $6.75 | 111.72K |
| Oct 26, 2026 | $7.00 | $7.09 | $6.63 | $6.89 | 104.8K |
| Oct 23, 2026 | $6.72 | $7.18 | $6.66 | $6.99 | 320.23K |
| Oct 22, 2026 | $6.75 | $6.80 | $6.73 | $6.80 | 111.42K |
| Oct 21, 2026 | $6.73 | $6.80 | $6.67 | $6.80 | 171.36K |
| Oct 20, 2026 | $6.70 | $6.78 | $6.68 | $6.68 | 62.35K |
| Oct 19, 2026 | $6.53 | $6.74 | $6.48 | $6.67 | 76.16K |
| Oct 16, 2026 | $6.46 | $6.65 | $6.40 | $6.53 | 160.78K |
| Oct 15, 2026 | $6.69 | $6.75 | $6.24 | $6.45 | 169.97K |
| Oct 14, 2026 | $6.74 | $6.79 | $6.615 | $6.64 | 80.26K |
| Oct 13, 2026 | $6.76 | $6.8025 | $6.64 | $6.78 | 86.81K |
| Oct 12, 2026 | $6.54 | $6.81 | $6.53 | $6.76 | 107.25K |
| Oct 9, 2026 | $6.62 | $6.73 | $6.535 | $6.59 | 57.97K |
| Oct 8, 2026 | $6.48 | $6.71 | $6.41 | $6.62 | 91.39K |
| Oct 7, 2026 | $6.39 | $6.58 | $6.385 | $6.54 | 104.53K |
| Oct 6, 2026 | $6.60 | $6.60 | $6.35 | $6.50 | 69.48K |
| Oct 5, 2026 | $6.13 | $6.61 | $6.11 | $6.585 | 90.37K |
The latest Smart Investors Daily articles mentioning CV.
Company
Market Activity
Research & News
CV research
Company profile and research snapshot.
CapsoVision Inc is a commercial-stage medical technology enterprise, innovates, manufactures, and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal (GI) system. Internal GI imaging facilitates earlier detection of colorectal cancer and other diseases, enabling more timely and effective treatment regimens for patients. The Company's core technology platform is an orally ingestable capsule including multiple cameras facilitating 360-degree imaging, light-emitting diodes for measurement, onboard memory storage, and battery life permitting recording and onboard storage of video images. The Company's products consist of the on-market CapsoCam Plus, directed at the small intestines, and the in-development CapsoColon 3D directed at the large intestines.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 27, 2026 | Benchmark | Speculative Buy | — |
| Dec 31, 2025 | Benchmark | Speculative Buy | — |
| Jul 28, 2025 | Benchmark | Speculative Buy | — |
No generated briefing is available yet.
Yahoo · Oct 24, 2026
CapsoVision (NASDAQ:CV) outlined its strategy to expand capsule endoscopy technology beyond its current small-bowel business into colon, pancreatic and esophageal cancer screening applications, highlighting its artificial intelligence capabilities, cloud-based workflow and upcoming regulatory submis
Yahoo · Oct 13, 2026
SARATOGA, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, David Garcia, Senior Vice President of Finance, and Doug Atkinson, Senior Vice President of Global Sales, will present at the 20th Annual LD Micro Main Event, taking place October 19-21, 2026, at the Luxe Sunset Boulevard Hot
Yahoo · Sep 28, 2026
AI-assisted reading tool designed to aid physician review of small bowel capsule endoscopy studies performed due to suspected bleeding using the CapsoCam Plus® systemSARATOGA, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that AI Highlights™, its AI-assisted reading tool for the CapsoCam Plus system, received clearance from the U.S. Fo
Benzinga · Sep 28, 2026
AI Highlights is designed to support physicians in the review of small bowel capsule endoscopy studies collected from adult and pediatric patients (over two years of age) in whom the study was performed due to suspected
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CV.
